Tempus, Predicta Biosciences to Offer Co-Branded WGS-Based Assay for Blood Cancers

The co-branded GenoPredicta assay combines flow cytometry and whole-genome sequencing to characterize hematologic malignancies and track MRD.

Tempus AI and Predicta Biosciences have teamed up to market GenoPredicta, a whole-genome sequencing (WGS)-based blood cancer profiling assay, to researchers of hematologic malignancies and measurable residual disease (MRD) monitoring, the companies announced on April 15.

The assay integrates flow cytometry with WGS characterize blood cancers from peripheral blood or bone marrow samples. It is currently available for exploratory research and clinical development programs, and available for research-use only across other indications. Financial terms of the deal were not disclosed.

“GenoPredicta offers a novel, unified solution for our life science partners and a comprehensive replacement for traditional, siloed testing,” Tempus Chief Scientific Officer Kate Sasser said in a statement. “By consolidating flow cytometry, cytogenetics, and WGS into one ultra-sensitive workflow, we can identify high-risk biomarkers and track clonal evolution from as few as 50 tumor cells. Crucially, because the assay delivers 100 percent concordance between peripheral blood and bone marrow, it can provide these deep insights while sparing patients from biopsies.”

GenoPredicta has been clinically validated in multiple myeloma and other plasma cell dyscrasias. It can identify single nucleotide variants, indels, copy number variants, and structural variants from as few as 50 tumor cells, corresponding to a sensitivity of one in a million cells, a threshold the companies say expands testing eligibility to patients with low tumor burden.